Next Article in Journal
Worldwide Occurrence and Investigations of Contamination of Herbal Medicines by Tropane Alkaloids
Next Article in Special Issue
Expression of Staphylococcal Enterotoxins under Stress Encountered during Food Production and Preservation
Previous Article in Journal
α-Conotoxin Decontamination Protocol Evaluation: What Works and What Doesn’t
Previous Article in Special Issue
ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessFeature PaperReview
Toxins 2017, 9(9), 282; https://doi.org/10.3390/toxins9090282

The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report

1
Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA
2
Department of Surgery, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA
*
Author to whom correspondence should be addressed.
Academic Editor: David J. Fitzgerald
Received: 15 August 2017 / Revised: 5 September 2017 / Accepted: 13 September 2017 / Published: 15 September 2017
(This article belongs to the Special Issue Heat-Stable Enterotoxins)
View Full-Text   |   Download PDF [583 KB, uploaded 15 September 2017]   |  

Abstract

Cancer immunotherapy is becoming a routine treatment modality in the oncology clinic, in spite of the fact that it is a relatively nascent field. The challenge in developing effective immunotherapeutics is the identification of target molecules that promote anti-tumor efficacy across the patient population while sparing healthy tissue from damaging autoimmunity. The intestinally restricted receptor guanylyl cyclase C (GUCY2C) is a target that has been investigated for the treatment of colorectal cancer and numerous animal, and clinical studies have demonstrated both efficacy and safety. Here, we describe the current state of GUCY2C-directed cancer immunotherapy and the future directions of this work. View Full-Text
Keywords: colorectal cancer; immunotherapy; vaccine; adenovirus; checkpoint inhibitor; immunotoxin; CAR-T cell colorectal cancer; immunotherapy; vaccine; adenovirus; checkpoint inhibitor; immunotoxin; CAR-T cell
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Baybutt, T.R.; Aka, A.A.; Snook, A.E. The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report. Toxins 2017, 9, 282.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top